Benzo[a]pyrene aggravates atopic dermatitis-like skin lesions in mice.
Rie YanagisawaEiko KoikeHirohisa TakanoPublished in: Human & experimental toxicology (2021)
Background: Benzo[a]pyrene (BaP) affects the immune system and causes mutagenic and carcinogenic effects. Purpose: We aimed to evaluate the effects of systemic exposure to BaP on mite allergen-induced atopic dermatitis (AD)-like skin lesions in mice. Methods: Mite allergen (Dermatophagoides pteronyssinus; Dp) was injected intradermally into the right ears of NC/Nga male mice on eight occasions every 2-3 days. Benzo[a]pyrene was administered intraperitoneally in the equivalent doses of 0, 2, 20, 200, or 2000 μg/kg/day, once a week on four occasions. Results: AD-like skin inflammation related to mite allergen worsened by BaP exposure at 2, 20 µg/kg/day doses; this was in parallel with eosinophil and mast cell infiltration and mast cell degranulation. A trend was also observed toward increased proinflammatory molecule expression, including macrophage inflammatory protein-1 alpha, interleukin (IL)-4, IL-13, and IL-18, in the ear tissue. However, 200 or 2000 µg/kg/day BaP attenuated the enhancing effects. In the regional lymph nodes, 2 µg/kg/day BaP with Dp enhanced antigen-presenting cell and T cell activation compared with Dp alone. Conclusions: This suggests that BaP exposure can aggravate Dp-induced AD-like skin lesions through TH2-biased responses in the inflamed sites and the activation of regional lymph nodes. Therefore, BaP may be responsible for the recent increase in AD incidence.
Keyphrases
- atopic dermatitis
- lymph node
- allergic rhinitis
- soft tissue
- wound healing
- oxidative stress
- high glucose
- diabetic rats
- drug induced
- single cell
- randomized controlled trial
- adipose tissue
- risk factors
- binding protein
- type diabetes
- mesenchymal stem cells
- early stage
- clinical trial
- cell therapy
- study protocol
- wild type
- long non coding rna
- small molecule